RJ Hamster
🐤 3 Surging Stocks Just Got the Ultimate Stamp…
| UnsubscribeMONDAY, DECEMBER 22ndGOOD MORNINGDespite headlines declaring the AI bubble has popped, recent data says otherwise. Micron’s massive earnings beat and bullish guidance, fueled by demand for high-bandwidth memory, highlight ongoing investment in AI infrastructure. Institutional accumulation and analyst upgrades across NVIDIA-adjacent names confirm smart money is still buying. Add in cooling inflation, expected Fed rate cuts, and a solid consumer backdrop, and the setup for 2026 remains strong. The S&P 500 is consolidating near highs and looks ready to rally into year-end. December’s tight trading range has reset key technical indicators just as Q4 earnings season approaches. Labor data remains firm, retail sales are solid, and earnings forecasts are rising across upcoming quarters. With JPMorgan reporting in just three weeks and momentum building, the market could easily break out in a classic Santa Claus Rally.Featured: A Backdoor Play on Starlink’s IPO for Less than $100? (Ad)  FINANCE2 Stocks to Avoid as Crypto Momentum WanesThe northeast United States wasn’t the only region gripped by bitter cold this month—a new winter has also hit the cryptocurrency market. Weak sentiment and choppy trading threaten Bitcoin with its worst yearly performance since 2022. What’s caused the cryptocurrency stallout in …READ THE FULL STORYFROM OUR PARTNERSBest $19 you’ll spend this year.A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his “One Ticker” approach works — and how readers can access the full service for a year at a steep discount.WATCH THE BRIEF DEMO HERETRANSPORTATION3 Dividend Growth Stocks Analysts Are Upgrading for 2026A single analyst’s rating and price target, the consensus rating and price target, for that matter, have little value to investors without the proper context. The context is the sentiment strength and trend, which for stocks like PepsiCo (NASDAQ: PEP), AbbVie (NYSE: ABBV), and United Parcel Servic…READ THE FULL STORYFINANCEThese 3 Banks Are Rallying Into Year-End, But Will It Continue?While artificial intelligence (AI) has dominated headlines for much of the year, and sent many tech stocks soaring, some of the strongest performance across equities has come from far less glamorous corners. Bank stocks are in the middle of a standout run, with the Financial Select Sector SPDR ETF…READ THE FULL STORYFROM OUR PARTNERS7 High-Yield Dividend Stocks You Need to See7 High Yield Dividend Stocks to Buy Now 💰Love steady payouts? This free report reveals 7 high-yield dividend stocks you need to know about. From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.PERFECT FOR INCOME-FOCUSED INVESTORS.CONSTRUCTION3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500The S&P 500 Index is indisputably the most referenced benchmark for tracking the performance of large-cap U.S. stocks. Each quarter, the S&P 500 Index Committee (a committee within S&P Dow Jones Indices) reassesses which stocks will or will not remain in the index. This typically resul…READ THE FULL STORYMARKETSThis ETF Caught a Major Tailwind After the Fed’s Rate CutAfter finishing 2024 with the third-best performance of the S&P 500’s 100 sectors, the financial sector is wrapping up 2025 with strong momentum that could carry into 2026. Over the past month, the sector has risen 4.18%. And after the Federal Reserve enacted its third and final interes…READ THE FULL STORYFROM OUR PARTNERSAI Continues to Surge—Here Are 2 Stocks Still Under $15Markets are volatile—but AI keeps rising. A new report reveals two under-the-radar AI stocks under $15 that could thrive in 2025’s uncertain market. These picks are backed by key trends most investors are missing.DOWNLOAD YOUR FREE REPORT: 2 AI STOCKS UNDER $15 FOR 2025CONSUMER DISCRETIONARYNike Beats on Earnings But Struggles in China and Faces TariffsThe last three years have not been kind to U.S. apparel giant Nike (NYSE: NKE). As of the Dec. 18 close, shares had dropped approximately 34%, with sales, margins, and profits all down significantly over the same period. A series of strategic missteps contributed to this, including weak product…READ THE FULL STORYUTILITIESIs the AI Boom a Bubble? These 2 Dividend Stocks Say NoAs 2025 winds down, tech investors are facing a familiar mix of excitement and anxiety. With AI stock valuations at historic highs, the question heading into 2026 is no longer whether AI is transformative—but whether the market has gotten ahead of itself. Recent news also contributed to som…READ THE FULL STORYMARKETS4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and MoreHundreds of exchange-traded funds (ETFs) launched in the last year alone, further crowding an already-dense field and making it more difficult for investors to assess which might be a good fit for their portfolios. Many ETF investors focus on a long-term strategy with these investments—easy…READ THE FULL STORYTECHNOLOGYMETA Rises Amid Tech Decline, Trump’s AI Order Praised By AnalystThe last few months of 2025 haven’t brought what investors in Meta Platforms (NASDAQ: META) hoped for. Through late October, shares were up around 28% on the year. Since then, the stock has given back around half those gains, and is now up only 14% (as of the Dec. 18 close). However, inve…READ THE FULL STORYTECHNOLOGYTL;DR: Why Reddit is the New Growth Stock to BeatReddit Inc. (NYSE: RDDT) is ending the year on a high note, having returned about 37% in 2025, relaunching a rally that seemed to flatline earlier in the fall. The online content-sharing platform is showing signs of rapid growth, with its user base, earnings, and engagement features all expandi…READ THE FULL STORYMONDAY’S EARLY BIRD STOCK OF THE DAYA Stock Being Downgraded:Gilead Sciences (NASDAQ:GILD)Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis….Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case ExplainedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, December 18, 2025 at 6:34 PM.Gilead Sciences Bull Case  The current stock price is around $120.40, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.Gilead Sciences, Inc. has received multiple upgrades from analysts, with a consensus target price of approximately $131.13, indicating potential for price appreciation.The company reported strong quarterly earnings, exceeding analyst expectations with a revenue of $7.77 billion, showcasing its robust financial performance.Gilead Sciences, Inc. has a solid return on equity of 51.86%, reflecting effective management and profitability, which can be attractive to investors.With a P/E ratio of 18.67, the stock may be considered reasonably valued compared to its earnings, suggesting it could be a good investment relative to its earnings potential.Gilead Sciences Bear Case Insider selling has been notable, with executives selling over 135,000 shares recently, which could signal a lack of confidence in the stock’s short-term performance.The stock has experienced a decline of about 2.3% recently, which may indicate volatility and potential challenges in maintaining its price level.Despite strong earnings, the company faces competition in the biopharmaceutical market, which could impact future growth and profitability.The debt-to-equity ratio stands at 1.03, suggesting that the company has a significant amount of debt relative to its equity, which could pose risks in economic downturns.Analysts have mixed ratings, with some holding a “Hold” rating, indicating uncertainty about the stock’s future performance.VIEW TODAY’S STOCK PICKThe Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can “catch the worm” when the market opens.  View as a Web PageIf you need help with your newsletter, don’t hesitate to email our U.S. based support team at contact@marketbeat.com.Unsubscribe © 2006-2025 MarketBeat Media, LLC. All rights reserved. 345 N Reid Pl. #620, Sioux Falls, South Dakota 57103-7078. United States..Today’s Bonus Content: Weird options glitch opens up weekly cash opportunities (Click to Opt-In) |
